Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 1
2020 1
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
GBD 2017 DALYs and HALE Collaborators. GBD 2017 DALYs and HALE Collaborators. Lancet. 2018 Nov 10;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3. Lancet. 2018. PMID: 30415748 Free PMC article.
BACKGROUND: How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. ...
BACKGROUND: How long one lives, how many years of life are spent in good and poor health, and how the population's state of health an …
MAGIC: once upon a time in consent management-a FHIR® tale.
Bialke M, Bahls T, Geidel L, Rau H, Blumentritt A, Pasewald S, Wolff R, Steinmann J, Bronsch T, Bergh B, Tremper G, Lablans M, Ückert F, Lang S, Idris T, Hoffmann W. Bialke M, et al. J Transl Med. 2018 Sep 14;16(1):256. doi: 10.1186/s12967-018-1631-3. J Transl Med. 2018. PMID: 30217236 Free PMC article.
In the context of multi-centre research initiatives and a multitude of clinical and epidemiological studies scalable and automatable measures for digital consent management are required. Modular form, structure, and contents render a patient's consent reusable for varying …
In the context of multi-centre research initiatives and a multitude of clinical and epidemiological studies scalable and automatable measure …
The Impact of Upcoming Treatments in Huntington's Disease: Resource Capacity Limitations and Access to Care Implications.
Guttman M, Pedrazzoli M, Ponomareva M, Pelletier M, Townson L, Mukelabai K, Levine A, Nordström AL, Reilmann R, Burgunder JM. Guttman M, et al. J Huntingtons Dis. 2021;10(2):303-311. doi: 10.3233/JHD-200462. J Huntingtons Dis. 2021. PMID: 33843690 Free PMC article.
BACKGROUND: The most advanced disease-modifying therapies (DMTs) in development for Huntington's disease (HD) require intrathecal (IT) administration, which may create or exacerbate bottlenecks in resource capacity. ...
BACKGROUND: The most advanced disease-modifying therapies (DMTs) in development for Huntington's disease (HD) require intrathecal (IT …